largely represented in these ACOs with a negative disparity; on average there were 11 FQHC represented in ACOs with a negative disparity compared to 0.9 FQHC in ACOs with a positive disparity (p<0.01).
INTRODUCTION AND OBJECTIVES:
Insurance status has been demonstrated to be a barrier to prompt urological care. Telephone surveys reveal that substantially fewer urologists accept Medicaid compared to Medicare or private insurance. There is a paucity of urologic literature evaluating discrepancies in wait times for Medicaid patients versus other forms of insurance. We sought to evaluate wait time disparities in academic urology programs for Medicaid compared to Medicare patients.
METHODS: The cohort was identified from the online listing of all ACGME accredited urology residency programs. An IRB-approved standardized script was used to contact each institution to determine if they accepted Medicaid patients. For institutions that accepted Medicaid, separate calls were made to establish the earliest appointment time available for a fictional patient with Medicaid and then Medicare insurance. Discrepancies in wait times between insurance type were compared. All statistical analysis was performed using SPSS v24.0.
RESULTS: All 131 ACGME accredited academic urology programs were surveyed. Of these, 10 (7.6%) did not accept new patients with Medicaid insurance. 13 institutions (9.92%) declined to participate in our study. There were 108 academic urology clinics in our final analysis. Of these, 59% (n¼64) had longer wait times for Medicaid patients. Overall, there was a significant difference (p<0.001) between the mean wait times for a new patient visit with Medicare (23 days, STD 20.8) versus Medicaid (35 days, STD 27.5 (NAC) prior to radical cystectomy (RC) for muscleinvasive bladder cancer (MIBC) has been steadily increasing over the last decade, the majority of patients are not receiving NAC. Little is known about the reasons as to why these patients do not receive NAC. Our objective was to evaluate the rate of patient refusal of NAC, and examine descriptive characteristics associated with patient refusal of NAC.
METHODS: Using the National Cancer Data Base, patients who underwent RC between 2004-2013 for a diagnosis of cT2 MIBC were included. Among patients who did not receive NAC, patients were categorized as (i) having been recommended NAC and refused, or (ii) not recommended NAC due to patient risk factors. Bivariable analysis was used to determine associations for not receiving NAC between age, gender, race, income level, insurance status, education level, type of facility, distance to oncology provider, and trend over time.
RESULTS: Of 8298 patients who underwent cystectomy, 524 did not receive NAC and had complete data regarding reasons for Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e125 declining treatment. 58% of those included were recommended NAC but refused (n ¼ 305), while 42% of patients were not recommended NAC due to risk factors (n ¼ 219). Over the defined timeframe, an increasing trend toward patient refusal of NAC was seen (49% over 2004-2007, 59% over 2008-2010, 63% over 2011-2013, p ¼ 0.06 INTRODUCTION AND OBJECTIVES: Delay in radical cystectomy (RC) for urothelial bladder cancer has been associated with decreased overall survival (OS). However, this association was observed before the increased adoption of neoadjuvant chemotherapy (NAC) . We sought to analyze the effect of delays in the NAC setting and the factors associated with delays using a large registry based cohort.
METHODS: Using the National Cancer Database, we identified patients who underwent NAC and RC for muscle-invasive urothelial bladder cancer from 2006-2013. Patients with metastatic disease and prior treatment with immunotherapy were excluded. Time points for delays from diagnosis to initiation of NAC and from diagnosis to RC were tested for association with survival. Logistic regression was used to identify factors associated with delays in treatment. Cox-proportional hazards models were used to examine the relationship of delays to OS.
RESULTS: Based on inclusion criteria, 2,034 patients were identified. Median time from diagnosis to initiation of NAC and diagnosis to RC were 39 and 155 days, respectively. Delays were defined as >10 weeks for diagnosis to NAC and >6 months for diagnosis to RC. On multivariate analysis, significant factors associated with delay to NAC included, black race (OR 2.20, 95% CI (1.17,3.48)), no insurance (OR 2.10, 95% CI (1.17, 3.78)), Medicaid insurance (OR 2.25, 95% CI (1.34, 3.80)), Medicare insurance (OR 1.51, 95% CI (1.16, 1.97)), reporting at academic hospital (OR 1.42, 95% CI (1.06, 1.91)), and diagnosis elsewhere than treatment hospital (OR 1.74, 95% CI (1.29, 2.34)). For delay to RC, significant independent factors were male gender (OR 1.36, 95% CI (1.06, 1.74)), black race (OR 1.64, 95% CI (1.06, 2.55)), no insurance (OR 1.89, 95% CI (1.14, 3.16)), Medicaid insurance (OR 1.84, 95% CI (1.16, 2.91)), Medicare insurance (OR 1.33, 95% CI (1.07, 1.65)), and diagnosis elsewhere than treatment hospital (OR 1.87, 95% CI (1.50, 2.33)). Delays in NAC or RC did not have a significant effect on OS, complete response (P0), or downstaging.
CONCLUSIONS: There are several factors associated with delays in treatment of muscle invasive bladder cancer, including race, insurance, and care transitions. In the setting of NAC, delays do not seem to have a significant effect on OS or pathological response. More studies are needed to determine the reasons for these socioeconomic differences in treatment times and if improvements can be made to improve access to care for invasive bladder cancer. 
There is an inferred benefit to regional lymph node dissection (LND) during radical nephroureterectomy (RNU) for high grade upper tract urothelial carcinoma (HG UTUC). We evaluated trends in utilization of regional LND using the National Cancer Database. We hypothesized that increased use of minimally invasive surgical approaches as well as lower volume RNU centers would be associated with LND utilization.
METHODS: We included adults undergoing RNU for pathologically confirmed HG UTUC from 2004-2012. We examined patient demographic, clinical, disease severity (i.e. clinical stage/nodal status), surgical, and hospital-level factors associated receipt of LND using multivariable logistic regression. Sensitivity analyses assessed for consistency of trends in LND use across clinical stage/nodal status as well across center volume of RNU experience (lowest quartile RNU performed over the study period, interquartile, and top quartile).
RESULTS: Of 11,258 patients undergoing RNU for HG UTUC, 2,028/11,258 (18%) were minimally invasive, and 1,009/11,258 (9%) utilized LND. LND was more common in recent years (5.8% in 2004 , 12.5% in 2012 .1 for surgery in 2010-2012 versus 2004-2006] ). LND rate for open RNU was 11.6% versus 6.3% for minimally invasive RNU (OR 0.50, . By 2012, open LND rate rose to 15.8%; minimally invasive LND remained stable at 6.4% (p<0.001). For RNU case volume 79 unique centers were represented, 18 centers were low (<2 cases/year), 40 were intermediate (2 to 4 cases/year) and 21 were high (5 cases/year). Center volume was associated with LND (16.9% in top quartile volume centers, compared with 5.5% in lowest quartile volume centers [OR 3.9, 
]).
CONCLUSIONS: Utilization of regional LND during RNU for HG UTUC increased over time, driven mainly by increased utilization during open RNU. LND was performed at a greater rate in higher volume centers, even after adjustment for disease severity, and may be a quality metric for oncologic management of HG UTUC.
Source of Funding: Data grant from National Cancer Database, a collaboration between the Commission on Cancer, the American Cancer Society and the American College of Surgeons.
